LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
760
via globenewswire.comBusiness & Companies

FDA approves Livsayis (cemdisiran) as first siRNA therapy in generalized myasthenia gravis

FROM THE WIRE · GLOBENEWSWIRE.COM

Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA new drug approval with quarterly dosing may strengthen Regeneron's commercial prospects.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Livsayis is FDA approved as the first and only siRNA therapy for generalized myasthenia gravis.
  2. 02It is the only treatment with four-times-a-year subcutaneous dosing.
  3. 03The approval is based on Phase 3 NIMBLE results.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.